In initial analyses, the mouse model showed a reduction in cardiac left ventricle ejection fraction (EF), coinciding with the development of a cardiomyopathy phenotype, but only after eight months of continuous tafazzin knockdown (Acehan et al, 2011; Soustek et al, 2011). This evidence concerns the gene TAFAZZIN and cardiomyopathy.